Development of an implantable infusion pump for sustained anti-HIV drug administration

International Journal of Pharmaceutics

Volumn 355, Issue 1-2, 2008, Pages 38-44

  Baert, Lieven ^a   Schueller, Laurent ^a   Tardy, Yanik ^d   Macbride, Doug ^d   Klooster, Gerben van't ^b   Borghys, Herman ^e   Clessens, Ellen ^e   Van Den Mooter, Guy ^f   Van Gyseghem, Elke ^f   Van Remoortere, Pieter ^a   Wigerinck, Piet ^c   Rosier, Jan ^a  

^a Chem Pharm Development   (Belgium)

^b Preclinical Development   (Belgium)

^c Discovery Research   (Belgium)

^d Research and Development Department of Codman SA   (Switzerland)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^f UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Codman pump; Continuous infusion; Darunavir; Experimental; HIV; Infusion pump; Protease inhibitor; Viscous solution

Indexed keywords

DARUNAVIR; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; RITONAVIR;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; CAPILLARY FLOW; CATHETERIZATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG POTENCY; INFUSION PUMP; NONHUMAN; PAIN; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; VISCOSITY;

ALGORITHMS; ANIMALS; ANTI-HIV AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; HIV PROTEASE INHIBITORS; INFUSION PUMPS, IMPLANTABLE; PHARMACEUTICAL SOLUTIONS; PILOT PROJECTS; REPRODUCIBILITY OF RESULTS; SPECTROPHOTOMETRY, ULTRAVIOLET; SULFONAMIDES; VISCOSITY;

EID: 41549165542     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.01.029     Document Type: Article

References (21)

1. Clotet B. Strategies for overcoming resistance in HIV-1 infected patients receiving HAART. AIDS Rev. 6 (2004) 123-130
2. ® Model 3000 Series constant-flow implantable pump with bolus safety valve. Information by the manufacturer Codman & Shurtleff of Raynham, Massachusetts, USA. http://www.codman.com/PDFs/3000%20pump.pdf.
3. ®, Model 3000 implantable constant-flow infusion pump. Information by the manufacturer Codman & Shurtleff of Raynham, Massachusetts, USA. http://www.codman.com/PDFs/Pain%2003.pdf.
4. Descamps D., Flandre P., and Calvez V. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA 283 (2000) 205-211
5. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents-A Working Group of the Office of AIDS Research Advisory Council (OARAC), October 10, 2006. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://AIDSinfo.nih.gov.
6. Dougherty P.M., and Staats P.S. Intrathecal drug therapy for chronic pain: from basic science to clinical practice. Anesthesiology 91 (1999) 1891-1918
7. Fogarty L., Roter D., Larson S., Burke J., Gillespie J., and Levy R. Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ. Couns. 2 (2002) 93-108
8. Kirschner D.E., and Webb G.F. Resistance, remission, and qualitative differences in HIV chemotherapy. Emerg. Infect. Dis. 3 (1997) 273-283
9. Koh Y., Nakata H., Maeda K., Ogata H., Bilcer G., Thippeswamy D., Kincaid J.F., Boross P., Wang Y.F., Tie Y., Volarath P., Gaddis L., Harrison R.W., Weber I.T., Ghosh A.K., and Mitsuya H. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 47 (2003) 3123-3129
10. Lachau-Durand, S., Raoof, A., Willems, B., Mamidi, S., Meuldermans, W., 2005. The effect of Ritonavir on the pharmacokinetics of TMC114 (Darunavir) in several preclinical species. Pharmaceutical Sciences Fair & Exhibition. Nice, France, June 12-17 (abstract PO-50).
11. Lamer T.J. Treatment of cancer-related pain: when orally administered medications fail. Mayo Clin. Proc. 69 (1994) 473-480
12. Lucas G.M., Chaisson R.E., and Moore R.D. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann. Int. Med. 131 (1999) 81-87
13. Palella F.J., Delaney K.M., and Moorman A.C. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338 (1998) 853-860
14. Portenoy R.K. Management of common opioid side effects during long-term therapy of cancer pain. Ann. Acad. Med. 23 (1994) 160-170
15. Poveda E., Blanco F., García-Gascó P., Alcolea A., Briz V., and Soriano V. Successful rescue therapy with darunavir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors. AIDS 20 (2006) 1558-1560
16. Ramírez-García P.R., and Côté J.K. Factors affecting adherence to antiretroviral therapy in people living with HIV/AIDS. J. Assoc. Nurs. AIDS Care 14 (2003) 37-45
17. Rathbun C., Farmer K., Stephens J.R., and Lockhart S.M. Impact of an adherence clinic on the behavioural outcomes and virologic response in treatment of HIV infection, a prospective, randomized, controlled pilot study. Clin. Ther. 27 (2005) 199-209
18. Sethi A.K., Celentano D.D., Gange S.J., Moore R.D., and Gallant J.E. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin. Infect. Dis. 37 (2003) 1112-1118
19. Simon V., Ho D.D., and Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 368 (2006) 489-504
20. Sutera S.P., and Skalak R. The history of Poiseuille's law. Ann. Rev. Fluid Mech. 25 (1993) 1-19
21. Winkelmüller M., and Winkelmüller W. Long-term effects of continuous intrathecal opioid treatment in chronic pain of non-malignant etiology. J. Neurosurg. 85 (1996) 458-467